DC-based immunotherapy of B-cell malignancies

Cytotherapy

Volumn 6, Issue 1, 2004, Pages 62-67

  Reichardt, V L ^a   Brossart, Peter ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Dendritic cells; Immunotherapy; Myeloma; NHL

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; KEYHOLE LIMPET HEMOCYANIN;

ANTIGEN PRESENTING CELL; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CELL TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PROTOCOL; DENDRITIC CELL; EXPERIENCE; HOST; HUMAN; LEUKAPHERESIS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REVIEW; TREATMENT OUTCOME; TUMOR IMMUNITY; WALDENSTROEM MACROGLOBULINEMIA;

B-LYMPHOCYTES; CANCER VACCINES; DENDRITIC CELLS; HUMANS; LEUKEMIA, B-CELL, CHRONIC; LYMPHOMA, FOLLICULAR; MULTIPLE MYELOMA; WALDENSTROM MACROGLOBULINEMIA;

EID: 1542345548     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240310004584     Document Type: Review

References (38)

1. Lynch RG, Graff RJ, Sirisinha S et al. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA 1972;69:1540-4.
2. Miller RA, Maloney DG, Warnke R et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982;306:517-22.
3. Kwak LW, Campbell MJ, Czerwinski DK et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327:1209-15.
4. Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B- cell lymphoma-long-term results of a clinical trial. Blood 1997;89:3129-35.
5. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5:1171-7.
6. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
7. + T cell lines from naive precursors. Eur J Immunol 1995;25:1206-11.
8. + CTLs from naive precursors. J Immunol 1994;153:996-1003.
9. Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517-26.
10. Timmerman JM, Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol 2000;164:4797-803.
11. Brossart P, Heinrich KS, Stuhler G et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999;93:4309-17.
12. Bergenbrant S, Yi Q, Osterborg A et al. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol 1996;92:840-6.
13. Osterborg A, Yi Q, Henriksson L et al. Idiotype immunization combined with granulocyte-macrophage colony- stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998;91:2459-66.
14. Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995;345:1016-20.
15. Massaia M, Borrione P, Battaglio S et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999;94:673-83.
16. Reichardt VL, Okada CY, Stockerl-Goldstein KE et al: Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biol Blood Marrow Transplant 1997;3:157-63.
17. Reichardt V, Okada C, Benike C et al. Idiotypic vaccination using dendritic cells for multiple myeloma patients after autologous peripheral blood stem cell transplantation. Blood 1996;88(Suppl 1):481a.
18. Reichardt VL, Okada CY, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999;93:2411-9.
19. Brown RD, Pope B, Murray A et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001;98:2992-8.
20. Ratta M, Fagnoni F, Curti A et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002;100:230-7.
21. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000;6:621-7.
22. Wen YJ, Ling M, Bailey-Wood R et al. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell- derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 1998;4:957-62.
23. Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 1999;83:215-22.
24. Cull G, Durrant L, Stainer C et al. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol 1999;107:648-55.
25. Titzer S, Christensen O, Manzke O et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000;108: 805-16.
26. Yi Q, Desikan R, Barlogie B et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol 2002;117:297-305.
27. Reichardt VL, Milazzo C, Brugger W et al. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica 2003;88:1139-49.
28. Wen YJ, Min R, Tricot G et al. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 2002;99:3280-5.
29. Trojan A, Schultze JL, Witzens M et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 2000;6:667-72.
30. Harig S, Witzens M, Krackhardt AM et al. Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood 2001;98:2999-3005.
31. Krackhardt AM, Witzens M, Harig S et al. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 2002;100:2123-31.
32. Krackhardt AM, Harig S, Witzens M et al. T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood 2002;100:167-73.
33. Vuillier F, Maloum K, Thomas EK et al. Idiotype-pulsed dendritic cells are able to induce antitumoral cytotoxic CD8 cells in chronic lymphocytic leukaemia. Br J Haematol 2003;120:243-50.
34. Orsini E, Guarini A, Chiaretti S et al. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res 2003;63:4497-506.
35. Dhodapkar MV. Dendritic cell-mediated immunization in macroglobulinemia. Semin Oncol 2003;30:305-8.
36. Gong J, Koido S, Chen D et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 2002;99:2512-7.
37. Davies FE, Dring AM, Li C et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003;102:4504-11.
38. Milazzo C, Reichardt VL, Muller MR et al. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 2003;101:977-82.